Laboratory information management system GoMeyra LIMS reported on Thursday the launch of the revolutionary new tech solution that triples daily testing capacity and provides test results within hours for medical laboratories and practices.
A Silicon Valley visionary and experienced systems IT developer created GoMeyra during the COVID-19 lockdown to address the testing crisis created by the pandemic, which exposed the drawbacks of antiquated systems and workforce shortages at labs across the country.
According to the company, its cloud-based solution enables unprecedented COVID-19 processing times for PCR, rapid antigen and antibody testing, as well as vaccine monitoring. It serves as the end-to-end processing platform for US labs, medical providers, contractors, corporations, universities, casinos, live entertainment productions and professional sporting events to handle large-scale testing, help control the coronavirus outbreak as well as get more Americans back to work, school, travel and normal activities.
The medical practice clients powered by GoMeyra LIMS include University of South Carolina in Columbia, SC, handling on-campus rapid testing; COVID Testing LLC in Orlando, managing student testing for the University of Central Florida; American Molecular Laboratories in Chicago; Millenia Advanced Scientific in Orlando, Vital Medical Diagnostics Inc in Houston; and Vitae Diagnostics in Southern California.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV